Bibliometric analysis reveals expanding ALKBH5 oncology literature and emerging tumor microenvironment hotspots, highlighting growing interest in RNA demethylase cancer therapeutics.
N6-methyladenosine (m6A) RNA modification is a key epitranscriptomic regulator implicated in cancer progression. Although ALKBH5, an m6A demethylase, has been widely studied, a systematic overview of the global research landscape remains limited. Bibliometric analysis can help address this gap by visualizing publication patterns and research hotspots. This study aims to delineate the developmental trends of ALKBH5 research in oncology from 2016 to 2025. Cancer-focused publications on ALKBH5 were retrieved from the Web of Science Core Collection for the period 2016–2025. Bibliometric and visualization analyses were conducted using VOSviewer, CiteSpace, and SCImago Graphica. From 2016 to 2025, 622 publications were identified, with most outputs originating from China and the United States. Co-citation analysis highlighted Chuan Chen as a highly influential author, and Frontiers in Oncology was the most productive journal. Keyword burst analysis indicated increasing attention to the tumor microenvironment, suggesting a growing focus on microenvironment- and immunity-related mechanisms. Overall, these findings suggest increasing research interest in the potential therapeutic relevance of ALKBH5 in cancer. This study summarizes publication trends and research frontiers in ALKBH5-related cancer research. The results provide a reference framework that may inform future mechanistic studies and clinical translation.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: